

Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.486, 2005-01, pp. : 11-11
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Similar drug persistency patterns for rivastigmine, donepezil in AD
Inpharma, Vol. 1, Iss. 1507, 2005-01 ,pp. :




Rivastigmine slows AD and cuts costs
Inpharma, Vol. 1, Iss. 1242, 2000-01 ,pp. :


Rivastigmine reduces need for neuropsychotherapeutics in AD
Inpharma, Vol. 1, Iss. 1504, 2005-01 ,pp. :


Rivastigmine slows AD and cuts costs
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 267, 2000-01 ,pp. :